Bullish investors cut cash levels to 15-year low, BofA says
MILAN, Feb 18 (Reuters) - Bullish investors cut cash levels to 3.5%, the lowest since 2010, as they went long stocks and "short everything else", a survey of investors from BofA Global Research showed on Tuesday.
BofA said equity investors rotated into bond-sensitive sectors, such as pharma, biotech, utilities and REITs, and to Europe, as a measure of investor fear of a global recession fell to a 3-year low and a trade war seen as no more than a tail risk.
Tech recorded its largest month-on-month allocation drop since September 2022, according to the monthly global survey of 168 participants with $401 billion of asset under management.
"Long Mag 7" remained the most crowded trade, BofA said, but US exceptionalism peaked, with 89% saying U.S. stocks are overvalued.
Related Articles
Caution on Short-Term Downside Risks for U.S. Stock Market
TradingKey - Last Friday, the U.S. Labor Department sharply revised downward its May and June nonfarm payroll figures by a combined 258,000 jobs, a reduction exceeding 90%. Meanwhile, July’s payroll increase came in at just 73,000, falling short of the 100,000 forecast.
From Ozempic to Wegovy: Growth and Risks Behind Novo Nordisk’s Q2 Performance
TradingKey - Novo Nordisk achieved revenue of $11.67 billion in Q2 of the 2025 fiscal year, a 19% increase year-over-year, but it fell short of market expectations. Growth was primarily driven by strong performance in obesity care and rare diseases.
MP Materials 2Q25 Earnings Preview: The New Stock Darling?
TradingKey - MP Materials will release its earnings for the second quarter of the fiscal 2025 on August 7th after the bell.
Bank of England August Rate Decision Preview: Pound Likely to Enter a Fluctuation Phase
TradingKey - On 7 August 2025, the Bank of England (BoE) will announce its policy interest rate decision. The prevailing market view suggests a high likelihood of a 25-basis-point rate cut, lowering the benchmark rate from the current 4.25% to 4%.
Eli Lilly FY2025 Second Quarter Earnings Preview
TradingKey - Eli Lilly’s Q2 2025 earnings report is expected to be released before the U.S. stock market opens on August 7. Mounjaro and Zepbound are the core drivers of Eli Lilly’s revenue growth, with GLP-1 receptor agonist drugs performing strongly in the diabetes and weight-loss markets..jpg)
